Methods and systems for radiation therapy involve administering a payload/combination of biocompatible high-Z and semiconductor NPs to tissue, such as a tumor or an eye. Ionizing radiation may be directed towards the payload, and ionized electrons generate Cerenkov radiation (CR). The CR interacts with semiconductor NPs to produce chemical species that are damaging to cells. The payload may be administered via injection or via a radiotherapy (RT) device that includes NPs in a biodegradable polymer matrix. Biodegradation of the polymer matrix, which results in release of its payload, may be remotely activated using, for example, electromagnetic or sound waves. The payload may include one or more immunologic adjuvants capable of promoting an immunologic response at remote sites (such as a metastatic tumors) that are separate from the site at which the NPs and adjuvants were administered.

A radiotherapy treatment system and method used for conducting radiographic X-ray imaging on a target organ during radiographic treatment. The system comprises (a) an x-ray beam source configurable to deliver an X-ray beam to a target organ, (b) optical means for converging and shaping said beam to a cone-shaped X-ray beam of photons which hit the target organ simultaneously, (c) multiple high-Z nanoparticles attachable to the target organ, said high-Z nanoparticles absorbing said X-ray radiation and emitting X-ray fluorescence (XRF) photons, (d) at least one XRF detector for detecting said XRF photons ejecting out of a patient's body, and (e) control means for controlling the radiotherapy treatment procedure.

The x-ray beam is focusable on a section in the target organ where the concentration of said high-Z nanoparticles leading to a desirable emission of said XRF photons, and in case the emission of said XRF photons decreases, the x-ray beam is movable to refocus on the section in the target organ where the emission of said XRF photons is desirable.

There is provided a novel emulsified composition containing a UV wavelength conversion substance and an organic oil-phase thickener.

This disclosure relates to compositions and methods for treating cancer by modulating the artemin pathway.

The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound,
wherein the PCNA interacting motif is X.sub.1X.sub.2X.sub.3X.sub.4X.sub.5 (SEQ ID NO: 1) and
wherein: X.sub.1 is a basic amino acid; X.sub.2 is an aromatic amino acid; X.sub.3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X.sub.4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X.sub.5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as antibiotics.

Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

The invention concerns a dye for use in a method of treating a vitreous opacity-related disease in a subject. The method preferably comprises administering the dye to the vitreous body of an affected eye of the subject; and irradiating at least part of the vitreous opacity, thereby inducing destruction of the vitreous opacity in the subject. The invention further relates to the use of a dye for photodestruction of a vitreous opacity in an eye of a subject, and to a method of photodestruction of a vitreous opacity in an eye of a subject, the method comprising: administering a dye to the vitreous body of the eye of the subject; and irradiating at least part of the vitreous opacity, thereby inducing destruction of the vitreous opacity of the subject.

We disclose a method, comprising administering, to a patient suffering from a cancer, a composition comprising a compound containing a gold atom; and administering, to a portion of the patient's body in which the cancer is present, radiation. We also disclose a kit comprising a composition comprising a compound containing a gold atom; and instructions to perform the method.

Cancer cells can be synchronized to the G2/M phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the G2/M phase. The optimal frequency and field strength will depend on the particular type of cancer cell being treated. For certain cancers, this frequency will be between 125 and 250 kHz (e.g., 200 kHz) and the field strength will be at least 1 V/cm.